Meeting News
-
A 40-Year Chase in SCLC: Where We’ve Been and Where We’re Going
Pioneer in SCLC research Dr. John D. Minna reflected on four decades of advancements in the field during his keynote address at the 2025 Hot Topics in SCLC.
-
A Real Tail in These Curves: A Look at Advances and Future Directions in SCLC
During a recent address at SCLC 2025, Dr. Charles Rudin discussed the progress being made in reducing the incidence of small cell lung cancer and in treating it.
-
COCOON Regimen Demonstrates Improvement in Dermatologic Toxicities
Dr. Nicolas Girard recently presented data that shows prophylactic treatment with oral and topical antibiotics and ceramide-based moisturizer significantly reduced adverse skin events.
-
Savolitinib Plus Osimertinib Offers Hope for Addressing Resistance, Progression
Dr. Myung-Ju Ahn said recent data from SAVANNAH show the combination produced a meaningful and durable response in patients whose cancer progressed after osimertinib.
-
Final MARIPOSA Analysis Confirms OS Improvement Versus Osimertinib Monotherapy
Drs. Chih-Hsin Yang and Pérol reviewed the latest findings and key takeaways during a presentation at the European Lung Cancer Congress.
-
Pathology Researcher Keith Kerr Receives 2025 Heine H. Hansen Award
During his award lecture at the European Lung Cancer Congress, Dr. Kerr said lung cancer treatment has benefited from the bridging of the historical divide between pathology and medical oncology.
-
Combination Therapies as Frontline Treatment for EGFR-Mutated NSCLC: Are the Rewards Worth the Risks?
During a TTLC debate, Drs. Helena Yu and Shirish Gadgeel weighed the pros and limitations of osimertinib monotherapy and combination therapies.
-
With Data on Her Side, Dr. Anne Tsao Dominates Debate on Merits of Chemo-IO for Mesothelioma
Lacking evidence to argue against combinations in this patient population, Dr. Penelope Bradbury, turned to humor to make her case.
-
Will Bispecific Antibodies Replace PD-(L)1 Targeted Agents?
Drs. Jonathan W. Riess and Greg Kalemkerian present opposing views regarding the therapeutic potential of novel targeted therapies.
-
Debate Leaves Audience Unconvinced that KRAS Inhibitors Deserve Promotion to First-Line Treatment
While Dr. Trever Bivona argued that KRAS inhibitors will join other seminal oncogene inhibitors, Dr. Rebecca Heist said the data has yet to demonstrate they outperform the current second-line standard of care.
View ILCN Archives
Provider Resources